Endothelin in chronic proteinuric kidney disease

Endothelin in Renal Physiology and Disease

Volumn 172, Issue , 2011, Pages 171-184

  Gagliardini, Elena ^a   Buelli, Simona ^a   Benigni, Ariela ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR;

ANIMAL; CHRONIC DISEASE; DRUG ANTAGONISM; HUMAN; PHYSIOLOGY; PROTEINURIA; REVIEW;

ANIMALS; CHRONIC DISEASE; ENDOTHELIN-1; HUMANS; PROTEINURIA; RECEPTORS, ENDOTHELIN;

EID: 84926078453     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000328697     Document Type: Chapter

References (68)

1. Grassmann A, Gioberge S, Moeller S, Brown G: ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587-2593.
2. Ruggenenti P, Remuzzi G: Kidney failure stabilizes after a two-decade increase: impact on global (renal and cardiovascular) health. Clin J Am Soc Nephrol 2007;2:146-150.
3. Brenner BM, Meyer TW, Hostetter TH:Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652-659.
4. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-1456.
5. Abbate M, Remuzzi G: Proteinuria as a mediator of tubulointerstitial injury. Kidney Blood Press Res 1999;22:37-46.
6. Abbate M, Zoja C, Remuzzi G: How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006;17:2974-2984.
7. Perico N, Benigni A, Remuzzi G: Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov 2008;7:936-953.
8. Benigni A: Tubulointerstitial disease mediators of injury: the role of endothelin. Nephrol Dial Transplant 2000;15(Suppl 6):50-52.
9. Dhaun N, Goddard J, Webb DJ: The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006;17:943-955.
10. Longaretti L, Benigni A: Endothelin receptor selectivity in chronic renal failure. Eur J Clin Invest 2009;39(Suppl 2):32-37.
11. Cybulsky AV, Stewart DJ, Cybulsky MI:Glomerular epithelial cells produce endothelin-1. J Am Soc Nephrol 1993;3:1398-1404.
12. Lyon-Roberts B, Strait KA, van Peursem E, et al: Flow regulation of collecting duct endothelin-1 production. Am J Physiol Renal Physiol 2011;300:F650-F656.
13. Benigni A, Remuzzi G: Endothelin antagonists. Lancet 1999;353:133-138.
14. Ahn D, Ge Y, Stricklett PK, Gill P, et al: Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 2004;114:504-511.
15. Gariepy CE, Ohuchi T, Williams SC, et al:Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 2000;105:925-933.
16. Ge Y, Bagnall A, Stricklett PK, et al:Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol Renal Physiol 2008;295:F1635-F1640.
17. Ishizawa K, Yoshizumi M, Tsuchiya K, et al: Dual effects of endothelin-1 (1-31):induction of mesangial cell migration and facilitation of monocyte recruitment through monocyte chemoattractant protein-1 production by mesangial cells. Hypertens Res 2004;27:433-440.
18. Simonson MS, Ismail-Beigi F: Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J Biol Chem 2011;286:11003-11008.
19. Morigi M, Buelli S, Angioletti S, et al: In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005;166:1309-1320.
20. Collino F, Bussolati B, Gerbaudo E, et al:Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 2008;294:F1185-F1194.
21. Morigi M, Buelli S, Zanchi C, et al:Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 2006;169:1965-1975.
22. Ortmann J, Amann K, Brandes RP, et al: Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004;44:974-981.
23. Zoja C, Morigi M, Figliuzzi M, et al:Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995;26:934-941.
24. Benigni A, Perico N, Gaspari F, et al:Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 1991;260:F331-F339.
25. Bruzzi I, Corna D, Zoja C, et al: Time course and localization of endothelin-1 gene expression in a model of renal disease progression. Am J Pathol 1997;151:1241-1247.
26. Zoja C, Benigni A, Camozzi D, et al:Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. Kidney Int 2003;64:857-863.
27. Zoja C, Liu XH, Abbate M, et al: Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. Exp Nephrol 1998;6:121-131.
28. Nakamura T, Ebihara I, Fukui M, Osada S, et al: Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice. Ren Physiol Biochem 1993;16:233-243.
29. Tazawa N, Okada Y, Nakata M, et al:Exaggerated vascular and renal pathology in endothelin-B-receptor-deficient rats with subtotal nephrectomy. J Cardiovasc Pharmacol 2004;44(Suppl 1):S467-S470.
30. Pfab T, Thone-Reineke C, Theilig F, et al:Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure. J Am Soc Nephrol 2006;17:1082-1089.
31. Yamauchi T, Ohnaka K, Takayanagi R, et al: Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 1990;267:16-18.
32. Wu Y, Feng B, Chen S, et al: Glucose-induced endothelin-1 expression is regulated by ERK5 in the endothelial cells and retina of diabetic rats. Can J Physiol Pharmacol 2010;88:607-615.
33. Hua H, Goldberg HJ, Fantus IG, Whiteside CI: High glucose-enhanced mesangial cell extracellular signal-regulated protein kinase activation and alpha1(IV) collagen expression in response to endothelin-1: role of specific protein kinase C isozymes. Diabetes 2001;50:2376-2383.
34. Benigni A, Colosio V, Brena C, et al:Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 1998;47:450-456.
35. Sasser JM, Sullivan JC, Hobbs JL, et al:Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007;18:143-154.
36. Fukui M, Nakamura T, Ebihara I, et al: Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med 1993;122:149-156.
37. Opocensky M, Kramer HJ, Backer A, et al:Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 2006;48:965-971.
38. Benigni A, Zoja C, Corna D, et al: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993;44:440-444.
39. Nakamura T, Ebihara I, Tomino Y, Koide H: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 1995;47:481-489.
40. Ebihara I, Nakamura T, Tomino Y, Koide H: Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis. Nephrol Dial Transplant 1997;12:1001-1006.
41. Nakamura T, Ebihara I, Fukui M, et al: Effect of a specific endothelin receptor A antagonist on glomerulonephritis of ddY mice with IgA nephropathy. Nephron 1996;72:454-460.
42. Thorner PS, Ho M, Eremina V, et al:Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol 2008;19:495-502.
43. Lasagni L, Ballerini L, Angelotti ML, et al:Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells 2010;28:1674-1685.
44. Cosenzi A, Bernobich E, Trevisan R, et al: Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol 2003;42:752-756.
45. Xu M, Dai DZ, Dai Y: Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats. Am J Nephrol 2009;29:252-256.
46. Nakamura T, Ebihara I, Fukui M, et al: Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995;44:895-899.
47. Gross ML, El-Shakmak A, Szabo A, et al:ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003;46:856-868.
48. Watson AM, Li J, Schumacher C, et al: The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2010;53:192-203.
49. Saleh MA, Boesen EI, Pollock JS, et al:Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010;56:942-949.
50. Remuzzi A, Perico N, Amuchastegui CS, et al: Short-and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40-49.
51. Gagliardini E, Corna D, Zoja C, et al:Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 2009;297:F1448-F1456.
52. Chade AR, Krier JD, Textor SC, et al:Endothelin-A receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. J Am Soc Nephrol 2006;17:3394-3403.
53. Perico N, Amuchastegui SC, Colosio V, et al: Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 1994;5:1139-1146.
54. Benigni A, Corna D, Maffi R, et al:Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 1998;54:353-359.
55. Wiggins RC: The spectrum of podocytopathies:a unifying view of glomerular diseases. Kidney Int 2007;71:1205-1214.
56. Ito T, Suzuki A, Imai E, et al: Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling. J Am Soc Nephrol 2001;12:2625-2635.
57. Poulsom R, Forbes SJ, Hodivala-Dilke K, et al: Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol 2001;195:229-235.
58. Sagrinati C, Netti GS, Mazzinghi B, et al:Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 2006;17:2443-2456.
59. Pernow J, Boutier JF, Franco-Cereceda A, et al: Potent selective vasoconstrictor effects of endothelin in the pig kidney in vivo. Acta Physiol Scand 1988;134:573-574.
60. Rabelink TJ, Kaasjager KA, Boer P, et al:Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 1994;46:376-381.
61. Honing ML, Hijmering ML, Ballard DE, et al: Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. J Am Soc Nephrol 2000;11:1498-1504.
62. Goddard J, Johnston NR, Hand MF, et al:Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-1193.
63. Raichlin E, Prasad A, Mathew V, et al: Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008;52:522-528.
64. Dhaun N, Macintyre IM, Melville V, et al:Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension 2009;54:113-119.
65. Dhaun N, Macintyre IM, Kerr D, et al:Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011;57:772-779.
66. Wenzel RR, Littke T, Kuranoff S, et al:Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-664.
67. Mann JF, Green D, Jamerson K, et al:Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-535.
68. Kohan DE, Pritchett Y, Molitch M, et al:Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011;22:763-772.